Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicinal Chemistry

Medicinal Chemistry

At Medicilon, chemistry and biology are integrated in every project we undertake. Our medicinal chemistry team is capable of flexibly applying computer chemistry to assist compound design process. We apply advanced drug discovery technologies, including proteolysis-targeting chimera (PROTAC), and antibody drug conjugation (ADC) to facilitate your projects.

We are also proud of our rich experience in innovative design and patent strategies that complement our technologies. In addition, we utilise responsive project management and effective communication to help optimize project delivery.

Download
Medicilon diamond icon.pngService
  • Medicilon’s medicinal chemistry services include:
    Feasibility assessment of new drug targetsHigh-throughput screening and discovery of active compounds based on  structural designSAR-based compound synthesis and SAR-based optimizationEstablishment of specific compound libraries (establishment of micromolecule compound library)Rapid synthesis of PROTAC molecules and ADC payloads, as well as lipids, glycolipids, and phospholipidsScreening of new hit compounds (from active compounds to discovery of lead compounds) Synthesis, discovery, and optimization of hit compoundsResearch on SARComputer-aided drug design (CADD) Processes from optimization of lead compounds to determination of preclinical drug candidatesPatent preparation and applicationELN system recordsMulti-parameter lead optimization for desired target molecule profiles (synthesis, discovery, and structural optimization of lead compounds)
Medicilon notebook icon.pngFeatures
  • An efficient team driven by deadlines
    The chemistry department of Medicilon has 1500 employees:About 40% have a PhD or Master's degreeMore than 10% of the employees have a foreign education and/or work experienceAverage working experience ofjunior research staff (researchers) : 3-5 yearsmiddle-level researchers (group leader level): 8-10 yearssenior level (director level and above): 15-20 years            Efficient team performance parameters: Fee for service (FFS) on-time delivery rate > 80%; Chemical reaction success rate > 85%;One compound delivered per full-time equivalent (FTE) each week;The number of reactions completed by each scientific researcher each week > 12.
  • Advanced equipment
    Supported by high-throughput chromatography and mass spectrometry and advanced processing software, Medicilon sets high standards for our compound screening and analysis, optimization of lead compounds, analysis of chemical and physical properties of compounds, and other drug R&D processes. Our 10,000 m2 laboratory in Shanghai Nanhui Industrial Park is equipped with a comprehensive library of instruments and is managed via a modern business model. We  guarantee the quality and efficiency of any project we undertake.
  • Our Medicinal Chemistry Department has established a PROTAC drug discovery platform that contains popular target protein ligands. We have also established libraries for high-affinity targeting protein small molecule (TPSM) and small molecular fragments, libraries for high-affinity ubiquitin ligase small molecule (E3SM) and small molecular fragments, and linker systems that include diversified bi-functional linkers (BF-Linker). Those compound libraries help to quickly and efficiently synthesize a large number of high-activity PROTAC  bi-specific small molecules, thus greatly accelerating the process of R&D.
  • Medicilon's nucleic acid drug discovery platform is an integrated and comprehensive platform for drug discovery, manufacturing and preclinical research. Medicilon has built an siRNA library with not only a rich inventory of monomers, but also a large library of monomer synthesis blocks, which can rapidly complete the synthesis of various types of modified monomers. Medicilon has a professional small nucleic acid drug development team, and several siRNA drug FTE projects have been completed and are in progress.
  • Each ADC R&D project provides its own challenges due to the varieties in the assembly of ADC molecules. With this in mind, Medicilon promises careful planning, meticulous execution and accurate results achievable because we have many years of practical experience and undertake effective communication with our clients.
Service Cases

Medicilon assists Ringene Biopharma 's SHP2 allosteric inhibitor RG001 tablet to be approved for clinical use.webp

Medicilon assists Ringene Biopharma 's SHP2 allosteric inhibitor RG001 tablet to be approved for clinical use

Learn More

Ringene Biopharma's pan-FGFR1-4 irreversible inhibitor RG002 tablets was approved for clinical use with the help of Medicilon one-stop preclinical biopharmaceutical R&D service platform.webp

Ringene Biopharma's pan-FGFR1-4 irreversible inhibitor RG002 tablets was approved for clinical use with the help of Medicilon one-stop preclinical biopharmaceutical R&D service platform

Learn More

Medicilon Assisted - The IND application of BIOT-001, the first self-developed new drug of Biotime Biotechnology, was approved by the FDA.webp

Medicilon Assisted - The IND application of BIOT-001, the first self-developed new drug of Biotime Biotechnology, was approved by the FDA

Learn More

For more service cases, please contact us:

Leave a message

Relevant laboratories
  • NMR
  • ICP-MS
  • mess-guided preparative HPLC
  • TECAN,-GENESIS-Work-Station-150
  • microwave reactor
  • NMR
  • chemistry lab
  • SFC
  • GC-MS
  • High activity laboratory
  • Overnight synthesis laboratory
  • Overnight synthesis laboratory
  • Overnight synthesis laboratory
Relevant articles